Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1
1999; Wiley; Volume: 80; Issue: 2 Linguagem: Inglês
10.1002/(sici)1097-0215(19990118)80
ISSN1097-0215
AutoresMarie Marchand, Nicolas van Baren, P. Weynants, Vincent Brichard, Brigitte Dr�no, Marie-H�l�ne Tessier, Elaine M. Rankin, Giorgio Parmiani, Flavio Arienti, Yves Humblet, A Bourlond, R Vanwijck, Danielle Li�nard, M. Beauduin, Pierre‐Yves Dietrich, Vincenzo Russo, Joseph Kerger, Giuseppe Masucci, Elke J�ger, Jacques De Grève, Jens Atzpodien, Francis Brasseur, Pierre G. Coulie, Pierre van der Bruggen, Thierry Boon,
Tópico(s)T-cell and B-cell Immunology
ResumoThirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. Int. J. Cancer 80:219–230, 1999. © 1999 Wiley-Liss, Inc.
Referência(s)